Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7 Wilms Tumor 1 Testicular Germ Cell Tumor 1 Prostate Cancer Metastatic 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic cancer, adult 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hepatic Veno-Occlusive Disease 1 Glioblastoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

pembrolizumab 92 Gemcitabine 56 Nivolumab 50 Cisplatin 39 atezolizumab 37 Carboplatin 30 avelumab 29 enfortumab vedotin 26 Docetaxel 23 Magnetic Resonance Spectroscopy 19 Mitomycin 17 Ipilimumab 17 Paclitaxel 16 Specimen Handling 14 durvalumab 11 toripalimab 10 sacituzumab govitecan 10 Pemetrexed 10 cabozantinib 9 Taxes 8 vinflunine 7 Cyclophosphamide 7 tislelizumab 6 Injections 6 Bevacizumab 6 pemigatinib 5 fludarabine 5 disitamab vedotin 5 Standard of Care 5 Radiosurgery 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × Hematologic Tests × Genitourinary × Clear all

NCT04566029 2025-12-10

AMI

Centre Hospitalier Universitaire de Nīmes

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡